Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Carboplatin Induction for Operable NSCLC
NCT00563160Phase 2Unknown
- Sponsor
- Hospital Authority
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Hospital Authority. Primary endpoint: Pathological Response Rate at 12 months. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00563160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563160.